Takhzyro (lanadelumab-flyo) — United Healthcare
Hereditary Angioedema (HAE) prophylaxis
Initial criteria
- Diagnosis of hereditary angioedema (HAE)
- For prophylaxis against HAE attacks
- Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Haegarda, Orladeyo)
Reauthorization criteria
- Documentation of positive clinical response while on Takhzyro therapy
- For prophylaxis against HAE attacks
- Not used in combination with other products indicated for prophylaxis against HAE attacks (e.g., Cinryze, Haegarda, Orladeyo)
Approval duration
12 months